|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).|
|Rapid review commissioned||05/10/2015|
|Rapid review completed||20/11/2015|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended at the submitted price|
Approved following confidential price negotiation for lenalidomide across all licensed indications (January 2018).